Allos AI

To add a bio or update company history, please click update information.

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

13 Jan 2026

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

Allos AI applies causal AI to reformulate complex generic drugs, improving delivery, tolerability and predictability while reducing development uncertainty.

Life Sciences
Oxford, United Kingdom
£4m
allos.ai
Update Information

More venture news

Semarion
31 Mar 2026
Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery
EquityLife Sciences
Sequential Bio
17 Mar 2026
Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients
EquityLife Sciences
Mestag Therapeutics
16 Mar 2026
Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies
EquityLife Sciences

Allos AI

News from Allos AI

Allos AI raises £4m in a seed round led by Oxford Science Enterprises to reformulate complex small-molecule generic drugs

More venture news

Semarion secures £2.9m in funding led by Parkwalk to accelerate cell-based drug discovery

Sequential secures £2.6m in funding led by Sparkfood and Corundum Systems Biology for non-invasive testing of skin health ingredients

Mestag Therapeutics secures £30m to advance fibroblast immunology cancer therapies